Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SkinBioTherapeutics ( (GB:SBTX) ) has shared an update.
SkinBioTherapeutics plc, a UK-listed life science company specialising in skin health technologies and consumer products, has increased its total number of ordinary shares in issue to 258,909,199 following the admission of 129,736 new shares arising from the exercise of share options. The updated share capital figure will serve as the new denominator for investors assessing whether they must disclose holdings or changes in their ownership under UK regulatory transparency rules, providing clarity for shareholders and ensuring ongoing compliance with market disclosure requirements.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £18.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative operating/free cash flow) despite strong revenue growth and a relatively conservative balance sheet. Technicals are supportive due to positive momentum, but overbought signals temper that strength. Valuation remains challenging because losses make the P/E less meaningful and no dividend yield is available.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics plc is a UK-based life science company focused on skin health, built around its proprietary SkinBiotix® platform developed with the University of Manchester. Its core business targets the skin healthcare market through five pillars, led by cosmetic skincare products using SkinBiotix® and AxisBiotix™ food supplements that exploit the gut-skin axis to address inflammatory skin conditions. The group partners with Croda plc, which markets SkinBiotix® as active ingredient Zenakine™, while AxisBiotix™ products are sold direct-to-consumer, via Amazon and in selected Superdrug stores, and the company is also pursuing acquisitions in complementary skincare and cosmetic areas to expand distribution, geography and manufacturing capabilities.
Average Trading Volume: 1,421,685
Technical Sentiment Signal: Buy
Current Market Cap: £48.52M
For a thorough assessment of SBTX stock, go to TipRanks’ Stock Analysis page.